vs

Side-by-side financial comparison of Applied Digital Corp. (APLD) and CASTLE BIOSCIENCES INC (CSTL). Click either name above to swap in a different company.

Applied Digital Corp. is the larger business by last-quarter revenue ($126.6M vs $87.0M, roughly 1.5× CASTLE BIOSCIENCES INC). On growth, Applied Digital Corp. posted the faster year-over-year revenue change (98.2% vs 0.8%). CASTLE BIOSCIENCES INC produced more free cash flow last quarter ($19.7M vs $-567.9M). Over the past eight quarters, Applied Digital Corp.'s revenue compounded faster (70.9% CAGR vs 9.2%).

BAE Systems Digital Intelligence is an international defence and security technology firm owned by BAE Systems. They specialize in delivering digital solutions that enable rapid, data-driven decision-making. Their services, solutions and products span customers in Law Enforcement, National Security, Government Departments and Government Enterprises, Critical National Infrastructure, Telecommunications, the Military, and Space.

Castle Biosciences Inc. is a commercial-stage diagnostic firm that develops and markets proprietary, clinically actionable tests for dermatological conditions such as melanoma and other skin cancers, plus rare diseases. It operates mainly in the U.S. healthcare market, focusing on segments with high unmet need for more accurate diagnostics to guide treatment choices.

APLD vs CSTL — Head-to-Head

Bigger by revenue
APLD
APLD
1.5× larger
APLD
$126.6M
$87.0M
CSTL
Growing faster (revenue YoY)
APLD
APLD
+97.4% gap
APLD
98.2%
0.8%
CSTL
More free cash flow
CSTL
CSTL
$587.7M more FCF
CSTL
$19.7M
$-567.9M
APLD
Faster 2-yr revenue CAGR
APLD
APLD
Annualised
APLD
70.9%
9.2%
CSTL

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
APLD
APLD
CSTL
CSTL
Revenue
$126.6M
$87.0M
Net Profit
$-14.4M
Gross Margin
20.6%
79.0%
Operating Margin
-24.5%
-4.4%
Net Margin
-11.4%
Revenue YoY
98.2%
0.8%
Net Profit YoY
89.6%
EPS (diluted)
$-0.07
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
APLD
APLD
CSTL
CSTL
Q4 25
$126.6M
$87.0M
Q3 25
$64.2M
$83.0M
Q2 25
$-33.3M
$86.2M
Q1 25
$52.9M
$88.0M
Q4 24
$63.9M
$86.3M
Q3 24
$60.7M
$85.8M
Q2 24
$43.7M
$87.0M
Q1 24
$43.3M
$73.0M
Net Profit
APLD
APLD
CSTL
CSTL
Q4 25
$-14.4M
Q3 25
$-16.9M
$-501.0K
Q2 25
$-52.5M
$4.5M
Q1 25
$-35.6M
$-25.8M
Q4 24
$-138.7M
Q3 24
$-4.2M
$2.3M
Q2 24
$-64.5M
$8.9M
Q1 24
$-62.8M
$-2.5M
Gross Margin
APLD
APLD
CSTL
CSTL
Q4 25
20.6%
79.0%
Q3 25
13.4%
77.5%
Q2 25
79.5%
Q1 25
7.1%
81.4%
Q4 24
18.0%
81.3%
Q3 24
-0.6%
81.8%
Q2 24
-9.1%
83.3%
Q1 24
-8.6%
81.0%
Operating Margin
APLD
APLD
CSTL
CSTL
Q4 25
-24.5%
-4.4%
Q3 25
-34.7%
-8.2%
Q2 25
-4.9%
Q1 25
-35.8%
-31.7%
Q4 24
-29.1%
4.7%
Q3 24
15.6%
5.9%
Q2 24
-68.4%
5.8%
Q1 24
-128.8%
-7.5%
Net Margin
APLD
APLD
CSTL
CSTL
Q4 25
-11.4%
Q3 25
-26.4%
-0.6%
Q2 25
157.8%
5.2%
Q1 25
-67.2%
-29.4%
Q4 24
-217.2%
Q3 24
-7.0%
2.6%
Q2 24
-147.5%
10.3%
Q1 24
-145.0%
-3.5%
EPS (diluted)
APLD
APLD
CSTL
CSTL
Q4 25
$-0.07
$-0.06
Q3 25
$-0.07
$-0.02
Q2 25
$-0.31
$0.15
Q1 25
$-0.16
$-0.90
Q4 24
$-0.66
$0.32
Q3 24
$-0.03
$0.08
Q2 24
$-0.57
$0.31
Q1 24
$-0.52
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
APLD
APLD
CSTL
CSTL
Cash + ST InvestmentsLiquidity on hand
$1.9B
$299.5M
Total DebtLower is stronger
$10.1M
Stockholders' EquityBook value
$1.4B
$470.9M
Total Assets
$5.2B
$578.6M
Debt / EquityLower = less leverage
0.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
APLD
APLD
CSTL
CSTL
Q4 25
$1.9B
$299.5M
Q3 25
$73.9M
$287.5M
Q2 25
$41.6M
$275.9M
Q1 25
$68.7M
$275.2M
Q4 24
$286.2M
$293.1M
Q3 24
$58.2M
$95.0M
Q2 24
$3.3M
$85.6M
Q1 24
$4.4M
$82.9M
Total Debt
APLD
APLD
CSTL
CSTL
Q4 25
$10.1M
Q3 25
$10.0M
Q2 25
$10.0M
Q1 25
$10.0M
Q4 24
$10.0M
Q3 24
$10.0M
Q2 24
$10.0M
Q1 24
$10.0M
Stockholders' Equity
APLD
APLD
CSTL
CSTL
Q4 25
$1.4B
$470.9M
Q3 25
$1.0B
$467.0M
Q2 25
$497.7M
$455.4M
Q1 25
$454.6M
$440.3M
Q4 24
$434.6M
$455.8M
Q3 24
$241.8M
$441.1M
Q2 24
$124.8M
$423.9M
Q1 24
$118.5M
$402.5M
Total Assets
APLD
APLD
CSTL
CSTL
Q4 25
$5.2B
$578.6M
Q3 25
$2.4B
$562.8M
Q2 25
$1.9B
$544.7M
Q1 25
$1.7B
$501.7M
Q4 24
$1.5B
$531.2M
Q3 24
$937.7M
$514.6M
Q2 24
$762.9M
$487.3M
Q1 24
$643.2M
$458.5M
Debt / Equity
APLD
APLD
CSTL
CSTL
Q4 25
0.02×
Q3 25
0.02×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.02×
Q2 24
0.02×
Q1 24
0.02×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
APLD
APLD
CSTL
CSTL
Operating Cash FlowLast quarter
$-15.8M
$26.9M
Free Cash FlowOCF − Capex
$-567.9M
$19.7M
FCF MarginFCF / Revenue
-448.6%
22.7%
Capex IntensityCapex / Revenue
436.1%
8.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-1.3B
$28.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
APLD
APLD
CSTL
CSTL
Q4 25
$-15.8M
$26.9M
Q3 25
$-82.0M
$22.6M
Q2 25
$6.9M
$20.8M
Q1 25
$5.9M
$-6.0M
Q4 24
$-52.3M
$24.4M
Q3 24
$-75.9M
$23.3M
Q2 24
$-34.1M
$24.0M
Q1 24
$38.8M
$-6.8M
Free Cash Flow
APLD
APLD
CSTL
CSTL
Q4 25
$-567.9M
$19.7M
Q3 25
$-331.4M
$7.8M
Q2 25
$-191.4M
$11.6M
Q1 25
$-251.6M
$-10.8M
Q4 24
$-223.3M
$16.8M
Q3 24
$-130.7M
$17.0M
Q2 24
$-88.9M
$18.8M
Q1 24
$-2.3M
$-16.0M
FCF Margin
APLD
APLD
CSTL
CSTL
Q4 25
-448.6%
22.7%
Q3 25
-516.1%
9.4%
Q2 25
574.8%
13.4%
Q1 25
-475.4%
-12.2%
Q4 24
-349.6%
19.5%
Q3 24
-215.3%
19.8%
Q2 24
-203.5%
21.6%
Q1 24
-5.4%
-21.9%
Capex Intensity
APLD
APLD
CSTL
CSTL
Q4 25
436.1%
8.3%
Q3 25
388.4%
17.9%
Q2 25
-595.4%
10.7%
Q1 25
486.6%
5.4%
Q4 24
267.8%
8.8%
Q3 24
90.3%
7.4%
Q2 24
125.4%
6.0%
Q1 24
95.0%
12.5%
Cash Conversion
APLD
APLD
CSTL
CSTL
Q4 25
Q3 25
Q2 25
4.60×
Q1 25
Q4 24
Q3 24
10.29×
Q2 24
2.69×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

APLD
APLD

HPC Hosting Business$85.0M67%
Data Center Hosting Business$41.6M33%

CSTL
CSTL

Dermatologic$48.6M56%
Non Dermatologic$38.4M44%

Related Comparisons